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In the crystal structure of the title compound, C24H22BrCl-
N4O3, there are C—H  O and C—H  Br intermolecular
hydrogen bonds, and also C—H  O, C—H  Br and C—
H  N intramolecular hydrogen bonds.
Comment
There has been widespread interest in the chemistry of
azepines due to their biological activities and their applica-
tions as anti-HIV drugs (Dyatkin et al., 1998). This is the first
human immuno-deficiency virus type 1 (HIV-1) non-nucleo-
side reverse transcriptase (RT) inhibitor to obtain regulatory
approval (Cywin et al., 1998). It prevents the damage to the
immune system and reduces the risk of developing AIDS-
related illness (Campiani et al., 1999). The compound 7-
chloro-5-cyclopropyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-
dibenzo[a,d]cyclohepten-11-one is an intermediate of a potent
anti-HIV drug, Nevirapine. The N-alkylation of the
compound by different alkyl and aryl halides leads to novel
molecules of biological interest.
In the title compound (I), C24H22BrClN4O3, the central
seven-membered ring is puckered. Atoms N5 and N13 deviate
from the plane defined by the atoms N3/C2/C16–C8/N7/C6–
C4 by 1.091 (3) and 0.952 (3) A˚, respectively. This deviation
may be attributed to the substitution of the 5-cyclopropyl and
10-(2-bromo-4,5-dimethoxybenzyl) groups. The total puck-
ering amplitude QT (Cremer & Pople, 1975) is 2.606 (4) A˚.
The structure exhibits intermolecular hydrogen bonding of
the types C—H  O and C—H  Br (Table 1 and Fig. 2). The
packing of the molecules, when viewed down the a axis (Fig. 2),
indicates that the molecules are interlinked by hydrogen
bonds.
Experimental
To a solution of 7-chloro-5-cyclopropyl-9-methyl-5,10-dihydro-
4,5,6,10-tetraazadibenzo[a,d]cyclohepten-11-one (0.5 g, 1.66 mmol)
in 5 ml of DMF, a mixture of 1-bromo-2-bromomethyl-4,5-dimeth-
oxybenzene (0.51 g, 1.66 mmol) and anhydrous powdered potassium
carbonate (0.688 g, 4.98 mmol) were added, and the mixture was
heated to 333 K for 6 h. The reaction was monitored by TLC. After
completion of the reaction, the solvent was removed under reduced
pressure and the product extracted with ethyl acetate. The organic
layer was dried with anhydrous sodium sulfate. The solvent was
evaporated to obtain the crude product which was purified over silica
gel using hexane and ethyl acetate (8:2) as an eluent for column
chromatography (yield: 80%). The pure product thus obtained was
recrystallized by slow evaporation of an acetonitrile solution. After
five days, pale-yellow crystals were obtained. Melting point: 461–
463 K. Elemental analysis data in (%) for C24H22BrClN4O3, calcu-
lated: C 54.41, H 4.19, N 10.57; found: C 54.43, H 4.17, N 10.54.
Crystal data
C24H22BrClN4O3
Mr = 529.82
Monoclinic, P21=c
a = 9.0680 (9) A˚
b = 16.7840 (9) A˚
c = 16.1960 (16) A˚
 = 107.260 (2)
V = 2354.0 (4) A˚3
Z = 4
Dx = 1.495 Mg m
3
Mo K radiation
 = 1.89 mm1
T = 295 (2) K
Block, pale yellow
0.30  0.25  0.25 mm
Data collection
MacScience DIPLabo 32001
diffractometer
! scans
Absorption correction: none
7627 measured reflections
4048 independent reflections
2933 reflections with I > 2(I)
Rint = 0.032
max = 25.0

Refinement
Refinement on F 2
R[F 2 > 2(F 2)] = 0.050
wR(F 2) = 0.155
S = 1.05
4048 reflections
301 parameters
H-atom parameters constrained
w = 1/[2(Fo
2) + (0.0944P)2
+ 0.2553P]
where P = (Fo
2 + 2Fc
2)/3
(/)max < 0.001
max = 0.40 e A˚
3
min = 0.68 e A˚3
Table 1
Hydrogen-bond geometry (A˚, ).
D—H  A D—H H  A D  A D—H  A
C21—H13B  Br29i 0.97 2.72 3.514 (5) 139
C22—H22A  O18 0.97 2.33 2.730 (6) 104
C22—H22B  Br29 0.97 2.71 3.239 (5) 115
C27—H27  O18ii 0.93 2.47 3.390 (6) 170
C17—H33B  N13 0.96 2.56 2.961 (5) 105
Symmetry codes: (i) xþ 1; y 12;zþ 12; (ii) xþ 1; y; z.
H atoms were placed at idealized positions and allowed to ride on
their parent atoms with C—H distances in the range 0.93–0.98 A˚;
Uiso(H) = 1.2Ueq(carrier atom) for all H atoms.
Data collection: XPRESS (MacScience, 2002); cell refinement:
SCALEPACK (Otwinowski & Minor, 1997); data reduction:
DENZO and SCALEPACK (Otwinowski and Minor, 1997);
program(s) used to solve structure: SHELXS97 (Sheldrick, 1997);
program(s) used to refine structure: SHELXL97 (Sheldrick, 1997);
molecular graphics: PLATON (Spek, 2003); ORTEPII (Johnson,
1976); software used to prepare material for publication: PLATON.
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Figure 1
The molecular structure of (I), with 50% probability displacement
ellipsoids.
